A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

NCT04874350 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cirrhosis
Sarcopenia

Interventions

DRUG: LPCN 1148
DRUG: Placebo

Sponsor

Lipocine Inc.